Movement Disorders

Here's some of what is coming soon to NeurologyLive® this week.

An interim analysis from TEMPO-4, presented as a late-breaker at MDS 2025, showed that tavapadon showed sustained long-term safety in Parkinson disease.

A phase 3 trial presented at the 2025 MDS Congress suggests that staged, bilateral magnetic resonance–guided focused ultrasound may improve motor symptoms for patients with Parkinson disease who experience motor complications.

A phase 2 study presented at 2025 MDS revealed that onabotulinumtoxinA significantly improved tremor-related disability compared with placebo in patients with upper limb essential tremor.

In phase 2a trial presented at MDS 2025, findings showed that VTX3232 achieved drug levels in plasma and cerebrospinal fluid that exceed the IC90 for NLRP3 inhibition by more than 3-fold.

New real-world data presented at MDS 2025 demonstrated that foslevodopa/foscarbidopa reduced motor fluctuations and improved quality of life in patients with advanced Parkinson disease over 6 months.

In this post-meeting Q&A, Claire Henchcliffe, MD, PhD, president-elect of the AALN, shared her reactions to AALN’s second annual meeting, the conversations that mattered most, and how the group plans to broaden and support neurology leadership in the year ahead.

PMD Alliance unveils a revamped website, enhancing accessibility and resources for the movement disorder community as it celebrates its 10th anniversary.

Johan Luthman, executive vice president and head of R&D at Lundbeck, discussed the rationale behind amlenetug, its mechanism of action, and the company’s ongoing efforts in multiple system atrophy through the phase 3 MASCOT trial.

Allison W. Willis, MD, MS, associate professor of neurology at the University of Pennsylvania School of Medicine, provided an overview of hot topics from the ANA 2025 program.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending October 11, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

The associate professor and clinician-scientist at the University of Toronto spoke to the current understanding of protein waste clearance in neurodegeneration. [WATCH TIME: 4 minutes]

New data reveals bemdaneprocel, an innovative cell therapy for Parkinson disease, shows promising safety and efficacy over 36 months, paving the way for future trials.

A new phase 2 trial explores probiotics' potential to alleviate depression and mood disorders in patients with Parkinson disease, linking gut health to mental well-being.

The neurologist at University of British Columbia discussed how abnormal brain plasticity influences Parkinson progression and highlighted the importance of integrating basic science with clinical care.

Results from the extension phase of the IB1001-203 study, presented as a late-breaker at MDS 2025, suggest N-acetyl-L-leucine prevented worsening of disease progression in patients with ataxia-telangiectasia.

New heatmap analysis reveals continuous apomorphine infusion significantly improves ON time and reduces OFF episodes in patients with Parkinson disease.

In the MOXIe open-label extension study presented at MDS 2025, omaveloxolone treatment was associated with no significant disease progression in bulbar function or upper limb coordination.

The chief of the Movement Disorders Division at Yale School of Medicine discusses the nuance around patient choice in Huntington disease testing and providing treatment regardless of confirmation. [WATCH TIME: 3 minutes]

The chief medical officer of Gain Therapeutics discusses the challenges that are unaddressed with currently available treatments for Parkinson, and how investigational treatments like GT-02287 might address those needs. [WATCH TIME: 3 minutes]

The neurologist at University of British Columbia discussed how breakdowns in brain organization and compensatory mechanisms may influence progression in Parkinson disease. [WATCH TIME: 5 minutes]

Valbenazine shows significant improvements in physical, social, and emotional outcomes for tardive dyskinesia patients, as revealed in a recent study.

Here's some of what is coming soon to NeurologyLive® this week.